Logo

Janssen Reports Results of Tremfya (guselkumab) in P-IIb (QUASAR) Induction Study for the Treatment of Active Ulcerative Colitis

Share this
Janssen Reports Results of Tremfya (guselkumab) in P-IIb (QUASAR) Induction Study for the Treatment of Active Ulcerative Colitis

Janssen Reports Results of Tremfya (guselkumab) in P-IIb (QUASAR) Induction Study for the Treatment of Active Ulcerative Colitis

Shots:

  • The P-IIb (QUASAR) induction study evaluates Tremfya (200/400mg, IV) vs PBO in 313 patients with UC with inadequate response/intolerance to conventional therapies or advanced therapies
  • The results showed that patients achieved clinical response @12wk. (61.4%/60.7% vs 27.6%), clinical remission rates (25.7%/25.2% vs 9.5%), symptomatic remission rates (50.5%/47.7% vs 20%), endoscopic improvement rates (30.7%/30.8% vs 12.4%), histo-endoscopic mucosal improvement (19.8/27.1% vs 8.6%), endoscopic normalization rates (17.8%/14% vs 6.7%) & safety data were consistent with safety profile for Tremfya
  • Tremfya is approved in the US, Canada, Japan, EU & other countries globally for PsO & active PsA

 Ref: PR Newswire | Image: Medical Dialogues

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions